ClinVar Miner

Submissions for variant NM_000275.3(OCA2):c.2425T>A (p.Phe809Ile)

gnomAD frequency: 0.00009  dbSNP: rs765779905
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000176361 SCV000228002 uncertain significance not provided 2016-11-22 criteria provided, single submitter clinical testing
Genetic Services Laboratory, University of Chicago RCV000504183 SCV000596138 likely pathogenic Tyrosinase-positive oculocutaneous albinism 2016-03-28 criteria provided, single submitter clinical testing
GeneDx RCV000176361 SCV001793690 likely pathogenic not provided 2022-12-21 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29345414)
Genome-Nilou Lab RCV000504183 SCV002039330 uncertain significance Tyrosinase-positive oculocutaneous albinism 2021-11-07 criteria provided, single submitter clinical testing
Invitae RCV000176361 SCV002135553 pathogenic not provided 2024-01-15 criteria provided, single submitter clinical testing This sequence change replaces phenylalanine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 809 of the OCA2 protein (p.Phe809Ile). This variant is present in population databases (rs765779905, gnomAD 0.05%). This missense change has been observed in individual(s) with ocular albinism (PMID: 29345414; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 195725). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt OCA2 protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic.
Revvity Omics, Revvity RCV000176361 SCV003814238 uncertain significance not provided 2019-08-14 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV003416081 SCV004113321 likely pathogenic OCA2-related condition 2022-08-24 criteria provided, single submitter clinical testing The OCA2 c.2425T>A variant is predicted to result in the amino acid substitution p.Phe809Ile. This variant has been reported along with a second OCA2 variant in at least two unrelated individuals with oculocutaneous albinism (Supplemental Table 3 in Lasseaux et al. 2018. PubMed ID: 29345414). Additionally, we have observed this variant here at PreventionGenetics in several individuals with oculocutaneous albinism who also harbored a second pathogenic variant in OCA2. This variant is reported in 0.048% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/15-28090112-A-T). This variant has conflicting interpretations in the ClinVar database including uncertain, likely pathogenic, and pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/195725). Given the evidence, we interpret c.2425T>A (p.Phe809Ile) as likely pathogenic.
Baylor Genetics RCV003468859 SCV004209034 likely pathogenic SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES 2023-05-17 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.